Dionex Corporation (DNEX)

[Pro-Life]

TMO buyout announced and a lawsuit pops up... read the terms and stop being greedy - sheeeeeeesh!!!

[buhg1b]

LONG BEACH (Mffais.com) - Ssga Small Cap Fund added the Dionex Corp (DNEX) company to their portfolio, by buying 1,931 shares as shown by filings made public on 2008-05-07.

The stock is currently owned by 214 funds/institutions with a total activity score of 0.41. With 54.63 % of owning funds reported recently buying shares, 13.91 % maintaining existing share level and 31.44 % selling shares. Full details for Dionex Corp (DNEX) available at http://www.mffais.com/dnex.html

[buhg1b]

Wedbush Morgan - 1 MAY 08 - downgrade Buy to Hold

http://finance.yahoo.com/q/ud?s=DNEX

[buhg1b]

Biotechnology instrumentation market to reach $4.6 billion by 2010

April 25, 2008 -- /PRWEB/ -- SAN JOSE, CA -- Demand for faster and more economical ways to produce drugs for the pharmaceutical industry, proteomics, genomics, functional genomics, and combinatorial chemistry industries have led to the advancement of biotechnology instrumentation in recent years. Growth is likely to be supported by major technological innovations in almost all the sectors, especially in chip-based products. Innovations in DNA sequencers, including single-molecule detection technologies, are likely to increase read lengths, decrease out-of-phase chemistry issues, and simplify sample preparation processes. With several drugs set for patent expiration in the near future, enhanced research activity for development of new drugs has escalated the demand for electrophoresis instruments.

The United States and Europe collectively dominate the worldwide biotechnology instrumentation market with an estimated 70 percent share of sales in 2008 as stated by Global Industry Analysts, Inc. Focus is largely centered on development of more advanced, smaller, faster, and highly automated analytical instruments that integrate analytical technologies. In the United States, demand for advanced instruments with more throughput abilities is rising across all academic and pharmaceutical laboratories due to the shift of research focus towards proteomics. The protein/ peptide synthesizers market in the United States is projected to be the fastest growing segment.

Europe, Germany, the United Kingdom, and France represent the major markets, accounting for about a 55 percent share of the biotechnology instrumentation market. Germany occupies a pivotal position in the European biotech market. The DNA sequencers market in Germany is projected to reach $69 million by 2010. Asia-Pacific is expected to be the center of future growth in worldwide biotechnology instruments market with an impressive CAGR of 7 percent over the period 2000 to 2010. The HPLC equipment and supplies market in the region is estimated at $207 million for 2008.

Key players profiled in the report include Agilent Technologies Inc., Affymetrix, Applied Biosystems, Beckman Coulter, Bio-Rad Laboratories Inc., Dionex Corporation, GE HealthCare, Gilson Inc, Hitachi High-Technologies Corporation, Perkin-Elmer, Shimadzu Scientific Instruments Inc., Thermo Fisher Scientific Inc, Varian Inc., and Waters Corporation.

The report titled "Biotechnology Instrumentation: A Global Strategic Business Report," published by Global Industry Analysts, Inc., analyzes the market over the period 2000 to 2015. Product segments analyzed in the report include DNA synthesizers, protein/peptide synthesizers, DNA sequencers, protein/peptide sequencers, HPLC equipment and supplies, and electrophoresis equipment and supplies. The report reviews recent industry activity, technological innovations, and product introductions of major market participants across various segments.

Visit www.strategyr.com

http://cr.pennnet.com/display_article/326851/15/ARTCL/none/TOPST/1/Biotechnology-instrumentation-market-to-reach-$46-billion-by-2010/

[buhg1b]

Global market for HPLC Systems & Accessories is projected to reach $3.0 billion by 2010. Future growth in the relatively mature HPLC market is expected from replacement sector, technology refinement and improvements, rather than from new product developments. These include device automation, software improvement and high speed and accuracy in analysis with the advent of LCMS systems.

San Jose, CA (PRWEB) April 22, 2008 -- Over the years, Liquid Chromatography has emerged as a workhorse technology in life sciences, pharmaceuticals, food and beverage, research and development, and industrial chemicals. Used alone or in combination with other high performance technologies, HPLC (High Performance Liquid Chromatography) is a versatile technique for efficient separation, quantification and characterization of constituents of complex chemical mixtures. Present day HPLC devices are capable of analyzing almost all types of biological compounds including small molecules that can be isolated or synthesized.

United States and Europe comprise the major markets, collectively accounting for an estimated 70% share of the global HPLC systems & accessories market for 2008, as stated by Global Industry Analysts, Inc. Proliferation of new applications, especially in biotechnology and pharmaceutical sectors, is one of the major factors driving growth. Other drivers include integration with complementary techniques or the growing shift towards 'hyphenated technologies', and growing acceptance and addition of new dimensions to the technique.

HPLC Systems & Accessories: A Global Strategic Business Report
HPLC Columns market in United States represents the largest market, with sales estimated at $303 million for 2008. Despite relatively mature conditions and resultant slow pace of growth, HPLC market in United States is benefiting from the introduction of fast LC technologies. Fast LC systems offer various advantages to research laboratories, which include superior resolution, high sensitivity, and enhanced throughput.

Asia-Pacific region is projected to record fastest growth, posting a CAGR of 7.5% over the period, 2000-2015. HPLC market in countries such as India is expected to witness rapid growth, propelled by an increase in life sciences research activities. HPLC pumps market in the region is projected to reach $79 million by 2010.

Germany is one of the leading producers and consumers of analytical instrumentation and laboratory equipment in Europe. HPLC is a popular technique employed by the bioanalytical, chemical and pharmaceutical industries in Germany. HPLC sample injectors market in Germany is estimated at $45 million for 2008.

Key players profiled in the report include Agilent Life Sciences and Chemical Analysis Group, Dionex Corp., ESA Biosciences Inc., Hitachi High Technologies America, Jasco Corporation, Knauer Scientific Instruments, Merck KgaA, Shimadzu Corp., Thermo Fisher Scientific Inc, Varian Inc., Waters Corporation, and ZirChrom Separations Inc.

The report titled "HPLC Systems & Accessories: A Global Strategic Business Report" published by Global Industry Analysts, Inc., analyzes the market over the period 2000-2015. Analysis is presented for United States, Canada, Japan, Europe, Asia-Pacific and Latin America. Product segments analyzed include HPLC Pumps, HPLC Sample Injectors, HPLC Columns, HPLC Detectors, Fraction Collectors and Accessories.

For more details of this research report please visit http://www.strategyr.com/HPLC_Systems_and_Accessories_Market_Report.asp.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

[buhg1b]

Tech Quartet Sounding Good
David Penn, TradingMarkets 04.10.08, 12:47 PM ET

Technology stocks may or may not be the best investments right now. But here are four tech stocks that short-term traders can look to that are likely to outperform the average stock over the next few days.

Seasonality experts from Yale Hirsch to Jim Cramer tell us that the time to buy tech stocks as an investment is in the summer, when technology stocks, along with most of the market, tend to be on the sleepy side. The theory calls for buying these overlooked equities in the summer and selling them as they rally into either back to school season in the fall or, if it's a good year, the holiday shopping season in the winter.

But for short-term traders, there's no reason to wait for the weather. Because of the wide universe of names and the types of businesses they run, just about any day may be a great day to trade tech stocks.
Special Offer: Which junior gold miners are the best buys? And should you be buying oil and energy stocks now? Click here for updated mining and energy trades in a free trial of Professional Timing Service.

And that includes the next five to eight days.
Click here for "Five Low-Risk Canadian Stocks," a free special report from The Canada Report.

As of late in trading on Wednesday, April 9, a number of stocks have had their Short Term PowerRatings upgraded, reflecting even greater potential for gains in the near term.

Some people misunderstand what we mean when we refer to stocks becoming more attractive as they move lower, confusedly thinking that this could potentially apply to all stocks.

This is wrongheaded. When we refer to stocks becoming more attractive as they move lower, this is always in the context of the stock trading above its 200-day moving average. We say it all the time. But it is an important point that apparently still bears repeating.

Strong stocks, stocks that are trading above their 200-day moving averages become more compelling as short-term trading candidates as they move lower and closer to that 200-day moving average. Stocks that pull back to the 200-day moving average are regressing to the mean.
Special Offer: George Putnam recommended Apple at $7.82 in 2003, giving subscribers a 10-bagger in three years and a 20-bagger in four! Click here for all of Putnam's current recommendations in The Turnaround Letter.

Our strategy is to look for stocks that are very extended from this mean, usually by rallying far above it, and to buy those stocks as they move closer to the mean.

Below are four stocks, all from the technology sector, that are now in the midst of those regressions to the mean. All four have earned Short Term PowerRatings upgrades as of late in the trading day on Wednesday, with one stock being upgraded from a thoroughly average six all the way to eight.

Axsys Technologies (nasdaq: AXYS - news - people ). Short Term PowerRatings upgrade from 8 to 9. RSI(2): 2.50


Actel Corp (nasdaq: ACTL - news - people ). Short Term PowerRatings upgrade from 8 to 9. RSI(2): 7.53


Dionex Corp (nasdaq: DNEX - news - people ). Short Term PowerRatings upgrade from 7 to 8. RSI(2): 10.30


Veeco Instruments (nasdaq: VECO - news - people ). Short Term PowerRatings upgrade from 6 to 8. RSI(2): 11.95


Our research found that stocks with Short Term PowerRatings of 8 outperformed the average stock by a margin of more than 8 to 1 within the next five days. Stocks with Short Term PowerRatings of 9 fared even better, besting the average stock by a margin of more than 13 to 1 over the same time period.

David Penn is senior editor at TradingMarkets.com. Click here for Today's Top 25 Stocks from TradingMarkets.com.

[buhg1b]

Net sales for the second quarter of fiscal 2008 were $98.0 million, compared with $83.5 million reported for the same period in the prior year, reflecting an increase of 17%. Operating income for the quarter was $22.8 million, an increase of 19% over operating income for the second quarter of fiscal 2007 of $19.2 million. Cash flow from operations during the quarter was strong at $12.0 million over cash flow from operations for the second quarter of fiscal 2007 of $18.3 million. Our gross profit margin for the quarter was 67.5% compared to 66.9% reported in the same period last year. Selling, general and administrative expenses were 36.6% of sales during the quarter, the same as was reported in the same period last year. Research and product development expenses for the quarter were 7.7% of sales, up slightly from the 7.3% reported in the same period last year. Diluted earnings per share grew 14% to $0.77 for the second quarter, compared to $0.68 reported in the same period last year. Net sales in the six months ended December 31, 2007 were $180.5 million, an increase of 15% compared with the $156.4 million reported in the first six months of fiscal 2007. Operating income was $38.7 million during the first six months of fiscal 2008, an increase of 18% over operating income for the same period during the prior year of $32.9 million. Cash flow from operations for the first six months of fiscal 2008 was $25.2 million. Gross profit margin for the six months ended December 31, 2007 was 66.5% compared to 66.4% during the same period in the prior year.
Demand from our life sciences and environmental customers was up strongly this quarter. Customer demand in our chemical/petrochemical and food/beverage markets was up significantly this quarter, while demand from our electronic and power customers was down this quarter. We experienced high teen's sales growth in ion chromatography this quarter. The sales growth was broad-based coming from both instrumentation and consumables
We are subject to the effects of foreign currency fluctuations that have an impact on net sales, gross profit and operating expenses. Overall, currency fluctuations increased reported net sales by $5.3 million, or 6% for the three months ended December 31, 2007 compared to the same quarter last year. Currency fluctuations increased reported net sales by $7.5 million or 5% for the six months ended December 31, 2007 compared to the same period last year. Diluted earnings per share for the first six months of fiscal 2008 were $1.30, representing a 16% increase over the same period during the prior year of $1.11.

Source: Quarterly report 10-Q